###### Key questions

What is already known about this subject?
=========================================

-   Psychosocial factors (ie, depression and social isolation) increase cardiovascular risk and are associated with adverse prognosis.

What does this study add?
=========================

-   Psychosocial determinants of, and potential responses to, secondary prevention was markedly different for men and women in a rigorously conducted clinical trial.

How might this impact on clinical practice?
===========================================

-   Early detection of important (and potentially modifiable) psychosocial risk factors via short screening tools should be routinely performed, with a potential need to modulate and apply secondary prevention strategies applied on a gender-specific basis.

Introduction {#s1}
============

It is well established that psychosocial risk factors modulate the development of cardiovascular disease[@R1] and can have deleterious effects on outcomes following a cardiac event.[@R2] There is now a large body of evidence to show that depression, reduced mental and physical health-related quality of life (HRQoL), stress, lack of social support, and cognitive impairment are highly prevalent in cardiac populations.[@R2] Consequently, adverse prognoses and elevated healthcare usage and costs ensue, potentially due to poor secondary outcomes as a consequence of adherence to suboptimal treatment.[@R9] [@R10] While supportive interventions in cardiac patients with depression have been shown to improve mental health, it is unclear if they improve cardiovascular outcomes.[@R10]

Distinct gender differences in the natural history of cardiac disease and presentation of acute cardiac events is apparent,[@R11] with higher rates of depression, asymptomatic presentation and cognitive impairment in women[@R9] than in men.[@R8] However, few studies have examined the impact of psychosocial risk factors in determining secondary cardiovascular events on a gender-specific basis.[@R2] We recently completed the multicenter Young @ Heart Study that examined the benefits of a nurse-led, home-based secondary prevention intervention (HBI) in a large cohort of cardiac inpatients (most with coronary artery disease (CAD)).[@R7] Compared to standard care, patients enrolled in HBI received comprehensive profiling, and an initial report (with recommendations) was sent to their primary care and specialist physician for clinical support and follow-up of any urgent deficits. Our nurse then implemented that plan (explicitly guided by expert secondary prevention guidelines) via a combination of outreached home visits, telephone follow-up, multidisciplinary support and referrals to other allied health professionals (depending on clinic needs). Our most important finding was that HBI resulted in a significant reduction in cardiovascular-related events; primarily hospitalisations for men. While the findings showed no overall differences between standard care and HBI, the nurse-facilitated HBI was not beneficial for women. All end points emphasised poorer health outcomes relative to standard care in women.[@R7] Moreover, hospital site was an independent correlate of cardiac events in women.[@R7] We therefore postulated that these findings were mediated by gender differences in psychosocial factors and the response to the patient--nurse interaction (as determined by the hospital site).

Study aims and hypotheses {#s1a}
-------------------------

On the bases of our initial findings,[@R7] we conducted a retrospective analysis of the Young @ Heart Study outcomes to examine the potential role of psychosocial factors and hospital site differences in determining a major acute cardiovascular event (MACE), independent of clinical profile. Specifically, it was hypothesised that there would be a differential contribution of psychosocial factors to subsequent MACE rates of all-cause mortality and unplanned cardiovascular-related hospitalisation based on gender. It was further anticipated that gender differentials would arise from a specific response to the study intervention and the nurse--patient interaction (as determined by the hospital recruitment site).

Materials and methods {#s2}
=====================

Study population {#s2a}
----------------

The design and primary outcomes of the Young @ Heart Study have been described previously.[@R7] [@R12] Recruited participants were elective and emergency inpatients at two hospitals in Brisbane, Australia; private health insurance holders (Bupa Australia), aged ≥45 years; diagnosed with chronic heart disease (principally CAD, chronic heart failure and arrhythmia (chronic atrial fibrillation)), discharged to home and required long-term management of symptoms and pharmacotherapy. Ethical approval was obtained from each administering hospital\'s ethics committees, and the study complied with the Declaration of Helsinki and CONSORT guidelines for reporting a pragmatic trial.[@R13] All participants gave written informed consent.

Subject profiling {#s2b}
-----------------

All participants were comprehensively profiled by the Young @ Heart Study nurses using standardised case report forms and validated assessment tools,[@R12] with information gained from a combination of health records and subject interviews.

Postdischarge management {#s2c}
------------------------

Participants were randomised (1:1) to receive postdischarge standard care, or the nurse-led standardised HBI programme[@R12] delivered by two trained specialist cardiac nurses from two administering hospitals (Hospital-A and Hospital-B). In brief, participants who were randomised to HBI received a comprehensive clinical assessment including an outreach home visit 1--2 weeks postdischarge (baseline), followed by repeat home visits and phone calls (depending on clinic needs) as part of an individualised programme of care (eg, support and appropriate referrals) with a strong focus on preventing progressive cardiac dysfunction to a subsequent MACE.

Psychosocial profile {#s2d}
--------------------

The *Patient Health Questionnaire-2* (PHQ-2) was used to assess the presence of a depressed mood.[@R14] Participants answered either 'yes' or 'no' to detect depressed mood and a loss of interest or pleasure in routine activities. A positive response to either question triggered further testing with the *Center for Epidemiologic Studies-Depression Scale (CES-D)*,[@R15] a reliable self-report questionnaire designed to identify depressive symptomatology from 20 items addressing how the respondent felt or behaved during the previous week. A score ≥16 on the *CES-D* signifies potential depression. The *12-item short-form health survey* was used to assess mental, physical and overall health related quality of life (HRQoL). Using the five-point Likert scale, respondents answered each of the 12 subscales measuring eight domains: (1) physical, (2) role physical, (3) bodily pain, (4) general health, (5) vitality, (6) social functioning, (7) emotional role and (8) mental health.[@R16] The *Montreal Cognitive Assessment (MoCA)*, was used to identify mild cognitive impairment (MCI) as defined by a score of \<26 of 30.[@R17] Last, assessment of social isolation was determined by household membership (eg, living alone or with others).

Clinical profile {#s2e}
----------------

Extent of each participant\'s concurrent comorbidity was measured using the Charlson Comorbidity Index adjusted for age.[@R18] Demographic profile, clinical profile (heart failure classification, kidney function, triglycerides, blood glucose) and cardiovascular risk factors (smoking habit, alcohol risk, cholesterol, body mass index, diabetes and hypertension), in addition to disease-specific profiling (eg, extent of CAD), were recorded from a standard patient assessment form.

Major acute cardiovascular events {#s2f}
---------------------------------

As part of the Young @ Heart Study, all hospitalisations were subject to blinded adjudication, and classified according to the discharge summary and principal diagnoses documented by the treating clinician. For the purpose of this study, a MACE was defined as any unplanned/emergency cardiovascular-related hospitalisation, or all-cause mortality, during a 2-year follow-up.

Statistical analyses {#s2g}
--------------------

All study analyses were performed retrospectively using SPSS (V.22, SPSS Inc, Chicago, Illinois, USA). Data are presented as mean (±SD) and median (IQR) for normally and non-normally distributed continuous variables, respectively. Numbers with percentages in parentheses are reported for categorical variables. Independent samples t test and Mann-Whitney U test were used to compare groups on normally and non-normally distributed continuous variables, respectively. Pearson\'s χ^2^ test of independence and OR with 95% CIs were used to explore categorical variables. Kaplan-Meier survival curves were generated, and a bivariate log-rank test calculated to determine whether there were differences in 2-year MACE (days to first event) according to gender, group randomisation and hospital site. Multivariate logistic regression analyses (backward elimination) were performed to determine the independent predictors of MACE for men and women separately. Independent variables included were baseline psychosocial factor variables, subject demographics, cardiovascular risk factors, concurrent comorbidity and clinical characteristics. Statistical significance was accepted at α\<0.05 (two-tailed).

Results {#s3}
=======

Study cohort {#s3a}
------------

A total of 602 participants were assessed, of whom 306 (51%) were randomised to receive the nurse-led HBI. Mean age of participants was 70±10 years and majority (n=431, 72%) were men. CAD (63%) was the most common reason for an index event (71% underwent a revascularisation procedure), followed by arrhythmia (20%) and heart failure (7%). From a psychosocial perspective, one in five participants (21%) lived alone, 23% had potential depressive symptoms (positive PHQ-2), and 28% had MCI.

Gender profile {#s3b}
--------------

Compared to men, women were significantly older (73±10 vs 68±9; p\<0.0001) and less likely to have received a tertiary education (23% vs 44%, OR 0.39; CI 0.26 to 0.59; p\<0.0001). They were also more likely to report potential depressive symptoms (positive PHQ-2: 30% vs 21%, OR 1.61, CI 1.07 to 2.40; p=0.020), have lower physical HRQoL scores (medium 39 (IQR 38 to 47) vs 46 (IQR 37 to 53); p\<0.0001), and live alone (46% vs 11%, OR 6.5, CI 4.26 to 9.93; p\<0.0001).

Cardiovascular events {#s3c}
---------------------

Overall, 165 patients (27%), experienced at least one MACE, including 22 (13%) fatal events, with 33 (20%) and 15 (9%) participants experiencing 2 and ≥3 events, respectively. The overall study flowchart is presented in online [supplementary figure](#SM1){ref-type="supplementary-material"} A. On average, MACE first occurred at 260±218 days post-index hospitalisation. Participants who experienced a MACE were significantly older (72±10 vs 69±9; p\<0.001), had more comorbidities (mean Charlson Index 5.7±2.7 vs 4.5±2.3; p=0.001), reduced physical HRQoL score (medium 39 (IQR 31 to 47) vs 46 (36 to 53); p\<0.001) and were more likely to have MCI (38% vs 25%; p=0.002).
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Gender-specific outcomes {#s3d}
------------------------

There were no significant gender differences in the contribution of all-cause deaths or hospitalisations to a MACE (27% of men vs 30% of women; p=0.431). In both women and men, the main reason for rehospitalisation was acute coronary syndrome (29% vs 36%), followed by arrhythmia (20% vs 15%), angina (18% vs 15%), and heart failure (13% vs 12%). Of the 114 men and 51 women who had a MACE, women were more likely to suffer from multiple events (39% vs 24%, OR 2.08, 95% CI 1.02 to 4.22; p=0.041).

[Table 1](#OPENHRT2015000356TB1){ref-type="table"} compares event-free status by gender and according to baseline characteristics. On an unadjusted basis, men and women who had experienced a MACE were significantly older, had a greater number of comorbidities and MCI compared with their non-MACE counterparts. For women only, there were differences in MACE rates according to the enrolling hospital (and by implication, the healthcare team applying the study intervention) with a greater proportion of women from Hospital-B who had a MACE (38% vs 19%; p=0.006). Alternatively, in men only, potential depressive symptoms were associated with a higher MACE rate (p=0.005).

###### 

Baseline characteristics of participants who had an event, or were event-free, in the entire cohort and according to gender

                                    All (N=602)      Men (N=431)      Women (N=171)                                                                                                    
  --------------------------------- ---------------- ---------------- ---------------- ------------- ---------------- ---------------- ------------- ---------------- ---------------- -------------
  Demographic profile                                                                                                                                                                  
   Age (years)                      70±10            69±9             72±10            **\<0.001**   68±9             70±10            **0.033**     71±10            77±8             **\<0.001**
   Education \>12 years (%)         228 (38)         176 (40)         52 (32)          0.051         145 (46)         43 (38)          0.150         31 (26)          9 (18)           0.247
  Study site                                                                           0.073                                           0.713                                           **0.006**
   Hospital A (%)                   258 (43)         197 (76)         61 (24)                        137 (74)         47 (26)                        60 (81)          14 (19)          
   Hospital B (%)                   344 (57)         240 (70)         104 (30)                       180 (73)         67 (27)                        60 (62)          37 (38)          
  Group randomisation                                                                  0.874                                           0.200                                           0.104
   HBI (%)                          306 (51)         223 (73)         83 (27)                        164 (76)         51 (24)                        59 (65)          32 (35)          
   Standard care (%)                296 (46)         214 (72)         82 (28)                        153 (71)         63 (29)                        61 (76)          19 (24)          
  Risk factor profile                                                                                                                                                                  
   BMI \>25 kg/m^2^ (%)\*           357 (68)         265 (68)         92 (66)          0.549         201 (72)         67 (69)          0.544         64 (59)          25 (58)          0.948
   Total cholesterol (mmol/L)       3.9±1.1          3.9±1.1          3.9±1.1          0.784         3.8±1.1          3.7±1.0          0.377         4.1±1.5          4.3±1.0          0.488
   Systolic BP (mm Hg)              139±23           139±23           140±25           0.530         138±23           138±24           0.971         143±23           147±25           0.374
   Diastolic BP (mm Hg)             75±12            75±11            73±14            0.072         76±11            74±13            0.176         73±12            71±15            0.294
   Type II diabetes (%)             125 (21)         83 (19)          42 (26)          0.081         63 (20)          27 (24)          0.391         20 (17)          15 (29)          0.059
   Blood glucose (mmol/L)           5.8 (5.2--6.8)   5.8 (5.2--6.8)   5.9 (5.2--7.0)   0.187         5.8 (5.2--6.8)   5.9 (5.2--6.9)   0.676         5.7 (5.1--6.4)   5.9 (5.2--7.8)   0.079
   Current smoker (%)               52 (9)           41 (9)           11 (7)           0.299         31 (10)          11 (10)          0.989         10 (8)           0                **0.034**
   High alcohol risk (%)            114 (19)         90 (21)          24 (15)          0.097         86 (27)          24 (21)          0.218         4 (3)            0                0.187
  Clinical presentation                                                                                                                                                                
   Charlson comorbidity[@R18]       4.9±2.5          4.5±2.3          5.7±2.7          **\<0.001**   4.4±2.3          5.4±2.6          **\<0.001**   4.8±2.2          6.3±2.7          **\<0.001**
   eGFR\<60 mL/min/1.73 m^2^ (%)†   103 (22)         58 (17)          45 (35)          **\<0.001**   35 (14)          28 (31)          **\<0.001**   23 (26)          17 (43)          0.053
  Functional status                                                                                                                                                                    
   NYHA class II, III, VI (%)       280 (47)         189 (43)         91 (56)          **0.006**     126 (40)         57 (51)          **0.036**     63 (53)          34 (67)          0.098
   Canadian class II, III, VI (%)   225 (38)         158 (36)         67 (42)          0.244         107 (34)         49 (45)          **0.048**     51 (43)          18 (35)          0.357
   6 min walk test (m)‡             305±119          312±116          285±126          **0.024**     328±111          309±117          0.158         268±115          226±127          0.065
  Primary diagnosis                                                                                                                                                                    
   Arrhythmia (%)                   119 (20)         80 (67)          39 (33)                        57 (18)          25 (22)                        23 (19)          14 (27)          
   CAD (%)                          377 (63)         289 (66)         88 (53)                        220 (70)         65 (57)                        69 (58)          23 (45)          
   Heart failure (%)                45 (7)           33 (8)           12 (7)                         14 (4)           7 (6)                          19 (16)          5 (10)           
   PAD (%)                          1 (0.2)          1 (0.2)          0                              1 (0.2)          0                              0                0                
   Renal disease (%)                5 (0.8)          1 (0.2)          4 (2)                          0                2 (2)                          1 (1)            2 (4)            
   Valve disease (%)                17 (3)           10 (2)           7 (4)                          9 (3)            5 (4)                          1 (1)            2 (4)            
   Other (%)                        37 (6)           22 (5)           15 (9)                         15 (5)           10 (9)                         7 (6)            5 (10)           
  Psychosocial factors                                                                                                                                                                 
   Patient lives alone (%)          127 (21)         86 (20)          41 (25)          0.144         36 (11)          13 (12)          0.943         50 (42)          28 (55)          0.112
  Quality of life§                                                                                                                                                                     
   SF-12 Physical                   43 (34--52)      46 (36--53)      39 (31--47)      **\<0.001**   47 (38--53)      41 (33--49)      **0.001**     40 (30--48)      34 (26--44)      0.080
   SF-12 Mental                     55 (48--59)      55 (48--59)      26 (24--28)      0.274         56 (49--60)      54 (47--60)      0.333         54 (48--59)      54 (46--58)      0.757
  Depression scores                                                                                                                                                                    
   PHQ-2, positive score (%)        141 (23)         96 (22)          45 (27)          0.159         59 (19)          31 (27)          **0.048**     37 (31)          14 (28)          0.658
   CES-D, total scores¶             20±10            21±11            19±10            0.576         19±10            21±10            0.558         23±11            17±9             0.107
   Potential depression (%)\*\*     90 (15)          59 (14)          31 (19)          0.098         32 (10)          23 (20)          **0.005**     27 (23)          8 (16)           0.312
  Cognitive function††                                                                                                                                                                 
   MoCA score                       27 (25--28)      27 (26--29)      26 (24--28)      **\<0.001**   27 (25--28)      26 (25--28)      **0.027**     27 (26--29)      26 (24--28)      **0.001**
   MCI (%)                          169 (28)         107 (25)         62 (38)          **0.002**     85 (27)          40 (35)          0.099         22 (19)          22 (44)          **0.001**

\*Assessed in n=596.

†Assessed in n=570.

‡Assessed in n=506.

§Assessed in n=591.

¶Assessed in patients with a positive PHQ-2 score (n=146).

\*\*Positive PHQ-2 plus CES-D ≥16.

††Assessed in n=593.

Bold value denotes statistically significance at \<0.05.

BMI, body mass index; BP, blood pressure; CAD, coronary artery disease; CES-D, Center for Epidemiologic Studies-Depression Scale; eGFR, estimated glomerular filtration rate; HBI, home-based intervention; MCI, mild cognitive impairment; MoCA, Montreal cognitive assessment. Data are expressed as mean±SD if normally-distributed, median (IQR) if not normally-distributed or percentages; NYHA, New York Heart Association; PAD, peripheral artery disease; PHQ-2, Patient health questionnaire-2 item; SF-12, 12-item short-form score.

[Table 2](#OPENHRT2015000356TB2){ref-type="table"} displays multivariate variables predicting a MACE using logistic regression (backward elimination procedure). Independent correlates of a 2-year MACE, overall, were higher Chalrson comorbidity, reduced physical HRQoL and MCI ([table 2](#OPENHRT2015000356TB2){ref-type="table"}). When examining men and women separately, greater comorbidity, low physical HRQoL and depressive status (positive PHQ-2 plus CES-D score ≥16) were independently associated with an increased risk of a 2-year MACE in men ([table 2](#OPENHRT2015000356TB2){ref-type="table"}). Conversely, in women, age, MCI at baseline and Hospital-B were associated with an equivalent increased risk.

###### 

Multivariate logistic regression models of predictors of a 2-year MACE in all patients and according to gender

  Predictor                     OR (95% CI)           p Value
  ----------------------------- --------------------- -----------
  All patients (n=546)                                
   Charlson comorbidity index   1.15 (1.06 to 1.25)   **0.001**
   SF-12 physical score         0.98 (0.96 to 1.00)   **0.020**
   Mild cognitive impairment    1.53 (1.02 to 2.30)   **0.040**
  Men (n=402)                                         
   Charlson comorbidity index   1.14 (1.04 to 1.25)   **0.004**
   SF-12 physical score         0.98 (0.96 to 1.00)   **0.030**
   Potential depression\*       1.95 (1.06 to 3.58)   **0.030**
  Women (n=162)                                       
   Age                          1.06 (1.02 to 1.12)   **0.008**
   Mild cognitive impairment    2.38 (1.09 to 5.18)   **0.030**
   Study-site (hospital-B)      2.32 (1.09 to 4.93)   **0.030**

\*Positive PHQ-2 plus CES-D ≥16.

Bold value was statistically significant at \<0.05.

SF-12, 12-item short-form score.

Group management and gender outcomes {#s3e}
------------------------------------

Overall, there was no difference in 2-year MACE according to group randomisation (82 (28%) standard care versus 83 (27%) HBI; p=0.874). However, gender-specific differences were found in the HBI group with proportionally more women than men experiencing a MACE during study follow-up (35% vs 24%, log-rank χ^2^=4.5; p=0.034). Alternatively, there were no differences for those randomised to standard care according to gender (24% vs 29%; p=0.313).

Group management by study-site by gender outcomes {#s3f}
-------------------------------------------------

There were notable differences in the overall pattern of 2-year MACE according to hospital site (24% from Hospital-A vs 30% from Hospital-B), however, it was not statistically significant (p=0.073). Proportionately, more women than men from Hospital-B experienced a MACE, although this was of borderline significance (38% vs 27%, log-rank χ^2^=3.8, p=0.052). Further, significantly more women from Hospital-A in the standard care group experienced a MACE (33% vs 12%; p=0.028). There was a similar (not significant) trend in women receiving HBI (43% vs 25%; p=0.064; [figure 1](#OPENHRT2015000356F1){ref-type="fig"}A) and no significant differences in men (HBI, p=0.553; standard care, p=0.888; [figure 1](#OPENHRT2015000356F1){ref-type="fig"}B).

![Kaplan-Meier event-free survival from a major acute cardiovascular event in women (A) and men (B), according to group randomisation and hospital enrolment.](openhrt2015000356f01){#OPENHRT2015000356F1}

[Figure 2](#OPENHRT2015000356F2){ref-type="fig"} shows the log-rank survival curves in Hospital-A and Hospital-B according to gender and group randomisation. The 2-year MACE rate for participants receiving HBI was similar for women and men enrolled from Hospital-A (22% vs 25%), although there was a significantly higher 2-year MACE rate in men only (29% vs 12%, p=0.045; [figure 2](#OPENHRT2015000356F2){ref-type="fig"}A). For participants receiving standard care, there were no significant gender differences observed for Hospital-B (p=0.761). However, in contrast with Hospital-A, there was a significantly higher 2-year MACE rate in women than men in subjects at Hospital-B (43% vs 25%; [figure 2](#OPENHRT2015000356F2){ref-type="fig"}B).

![Kaplan-Meier event-free survival from a major acute cardiovascular event in patients recruited from Hospitals A (A) and B (B), according to group randomisation and gender.](openhrt2015000356f02){#OPENHRT2015000356F2}

Discussion {#s4}
==========

We undertook a post hoc analysis of a nurse-led secondary prevention program[@R7] to determine the impact of psychosocial factors and/or hospital site on 2-year MACE according to gender. Overall, we found that more women than men experienced a MACE. Increasing comorbidity, reduced physical HRQoL and MCI independently predicted a 2-year MACE. In men only, independent correlates of a MACE were reduced physical HRQoL, increasing comorbidity and depressive status, whereas independent correlates for women were hospital site, older age and MCI. We found a markedly different response to the HBI in women from one recruitment hospital only. These findings suggest that, independent of clinical profile, different psychosocial factors contribute to a 2-year MACE in men and women exposed to a secondary prevention programme for cardiovascular disease. Additionally, patient--nurse interaction, particularly in women, may influence the way patients respond to the programme delivered in the home.

Findings from the current study support the hypothesis that in a sample of predominantly CAD patients, psychosocial factors can differentially influence secondary cardiovascular outcomes in men and women. Our findings also agree with previous research to show that those cardiac patients with psychosocial risk factors including depressive symptoms,[@R3] [@R4] reduced physical but not mental HRQoL,[@R5] and impaired cognitive function[@R8] [@R19] have poorer outcomes and greater mortality risk. Moreover, we have further demonstrated gender-specific psychosocial risk factors. The finding that women, overall, who had a 2-year MACE, were more likely to have MCI, is congruent with previous research demonstrating that MCI predicts health outcomes and mortality.[@R8] [@R19] This may be explained by a limited ability to comprehend and adhere to medical treatments as a result of greater cognitive impairement.[@R8] It is possible that MCI as a predictor of a 2-year MACE in women may have been influenced by a combination of factors including old age, more likely to be living alone and depressed, which is common among cardiac patients with MCI.[@R9]

As with previous studies, we found more depressive symptoms in women than men;[@R9] [@R20] however, men with depressive symptoms were almost twice more likely to have a MACE. It is possible that men with depressive symptoms in our study benefited from the additional support provided in HBI leading to improved mood, lower inflammation[@R21] and fewer adverse events. Moreover, the finding that reduced physical, but not mental HRQoL also predicted a MACE in men supports earlier studies in cardiac patients.[@R5] It is possible that the contributing factors of a MACE for men might be psychological, since depressed cardiac patients were more likely to report worse physical HRQoL than non-depressed patients,[@R22] and as observed in men in our current study. Contrary to previous studies,[@R2] [@R23] social isolation did not predict a 2-year MACE according to gender, suggesting that social isolation is a non-gender-specific predictor of a secondary cardiac event.[@R2] [@R7]

We found that the patient--nurse interaction, as reflected by hospital site, predicted a 2-year MACE. The finding that women did not acquire the same benefit at one hospital, even after adjusting for clinical characteristics and psychosocial factors, further supports our initial findings.[@R7] Differential outcomes were seen between hospital sites, despite controlling for treatment fidelity by conducting intensive, standardised, prestudy and ongoing training for the two cardiac nurses who delivered the HBI programme at respective hospitals. One explanation may be due to confounding factors impacting beyond intervention fidelity (eg, personality, beliefs, attitudes) of trained personnel delivering the intervention. Moreover, unequal patient numbers (130 patients in Hospital-A vs 176 patients in Hospital-B) might cause an unbalanced/overwhelming caseload management for Hospital-B. Recruitment of additional nurses in future studies, especially for busier sites, may alleviate the potentially high work load on these nurses. Taken together, our findings support earlier work demonstrating that women may respond differently than men to HBI.[@R24]

These observations are important as they present a need to re-evaluate current secondary prevention programmes by addressing gender differences in psychosocial and cognitive factors associated with increased risk of future cardiac events. Through prompt intervention to eliminate/reduce the psychosocial risks (particularly depression and diminished physical HRQoL in men) and cognitive impairment (especially for women) detected via routine screening using brief measures as per HBI, there is potential to prevent adverse health outcomes in cardiac patients. Future studies are required to test this hypothesis. Collectively, these findings support a collaborative care approach where appropriate referral can be initiated when necessary, linking patients with cardiovascular and mental health clinicians so that patients at risk of MACEs can receive early intervention of tailored, gender-specific, integrated treatments and lifestyle modifications.[@R6] [@R20] One unique aspect of nurse-led programmes is not only recommended routine screening for depression following a cardiac event[@R25] [@R26] but also other pertinent psychosocial risk factors including HRQoL, social isolation, and cognitive impairment.

Nurse-led, multidisciplinary, home-based disease management programmes have shown to improve recovery and reduce hospitalisations in cardiac patients,[@R27] [@R28] principally in men but not women.[@R7] However, evidence for the way in which psychosocial risk factors modulate how patients respond to secondary prevention programmes, especially for gender, are limited.[@R2] Our study has attempted to address this issue by providing a greater understanding of the differential gender effects of nurse-led HBIs. Consequently, our findings reinforce the need for a 'patient-centred' approach to secondary prevention[@R29] with a major consideration of the potentially different needs of men and women. Simultaneously, they are a timely reminder of 'operator dependence' in applying complex disease-management interventions with the potential to trigger a 'clinical cascade' that can provoke more hospital activity.[@R30] However, this is a hypothetical construct and needs to be tested in future studies. Additionally, over-reporting by women who may be more attentive to their symptoms, and possible under-reporting by men may explain the gender differences. Furthermore, anxiety and stress, especially job-related stressors, are factors related to poor health outcomes,[@R2] [@R9] however, we did not measure these, so future studies exploring these possible links are warranted. Future research exploring cardiac management programmes that are gender-specific and tailored to the individual, by way of addressing psychosocial risk using brief screening measures to profile patients, and factors influencing patient compliance such as the response to personalised care are urgently required.

A number of limitations influence the cautious interpretation of these data. First, this was a post hoc analysis, and we did not prospectively profile patients from a psychosocial perspective in anticipation of the initial findings. Additionally, the selective choice of only two hospitals and recruitment of privately insured patients who are likely to have higher education and income levels may bias results. The cohort tested were predominantly patients hospitalised with CAD, however, a sensitivity analysis indicated there were no differences in the outcomes seen in the pooled cohort. Furthermore, we acknowledge the risk of multiple testing and the risk of type I error, and future studies are therefore needed to replicate our results. Additionally, secondary prevention medication adherence was not accounted for as possible predictors, which may have influenced event rates. Finally, with the analyses being exploratory, results from this trial need to be confirmed in larger hypothesis-driven clinical studies.

Conclusion {#s5}
==========

These data, from a large nurse-led, multidisciplinary, secondary prevention programme further support the hypothesis that the psychosocial profile of acute cardiac patients who experience a MACE differs between men and women. Notably, overall depressive status and physical HRQoL was a significant predictor of a MACE in men, and MCI and administering hospital in women. This study has demonstrated that screening cardiac patients according to psychosocial risk and ongoing monitoring can predict poor health outcomes. Also, who delivers the intervention is another important factor as this will have an impact on how the patient benefits from the intervention. Future research exploring cardiac management programmes that are tailored to such profiling, particularly on a gender-specific basis, given an apparently differential response to more personalised care, are required. Finally, these data have important implications for the delivery of such care, to ensure intervention fidelity, and that secondary prevention is appropriately tailored to the patient according to individual responses to this care.
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